Core Insights - The report summarizes the financial performance of Cathay Biotech for the first half of 2025, highlighting significant growth in total assets, revenue, and net profit [1]. Financial Performance - Total assets increased to ¥23.82 billion, up 25.23% from ¥19.02 billion at the end of the previous year [1]. - Operating revenue reached ¥1.67 billion, reflecting a 15.68% increase compared to ¥1.44 billion in the same period last year [1]. - Total profit amounted to ¥342.11 million, a rise of 21.81% from ¥280.87 million year-on-year [1]. - Net profit attributable to shareholders was ¥296.45 million, marking a 23.67% increase from ¥239.71 million in the previous year [1]. Shareholder Information - The total number of shareholders as of the report date was 11,714 [2]. - Major shareholders include Shanghai Yaoxiu Biotechnology Partnership (35.29% ownership) and Cathay Industrial Biotech Ltd. [3]. Research and Development - The report indicates a focus on R&D, although specific percentages or figures related to R&D investment as a proportion of revenue were not provided in the excerpts [2].